Literature DB >> 22875796

USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure.

Monica Sigovan1, Warren Gasper, Hugh F Alley, Christopher D Owens, David Saloner.   

Abstract

PURPOSE: To determine the feasibility of using ferumoxytol-enhanced magnetic resonance (MR) angiography to depict the vasculature of hemodialysis fistulas and improve image quality compared with nonenhanced time-of-flight (TOF) MR angiography.
MATERIALS AND METHODS: The study was institutional review board approved and was in compliance with HIPAA regulations. All participants provided written informed consent. TOF and first-pass ferumoxytol-enhanced MR angiography were performed in 10 patients with upper extremity autogenous fistulas. Ferumoxytol was administered as a bolus solution containing 430 μmol of elemental iron. A qualitative comparison was performed on maximum intensity projection images. Lumen depiction was evaluated by using a five-point scale. The uniformity of intraluminal signal intensity was measured as the ratio between the mean signal intensity of the entirety of the imaged fistula and its standard deviation. The contrast-to-noise ratio (CNR) between intraluminal signal and adjacent tissue was evaluated as a function of image acquisition time. Lumen depiction scores, luminal signal heterogeneity, and CNR efficiency were compared between TOF and ferumoxytol-enhanced MR angiography by using a Wilcoxon-Mann-Whitney test.
RESULTS: Flow artifacts were greatly reduced by the use of ferumoxytol-enhanced MR angiography. Ferumoxytol-enhanced MR angiography had significantly better performance than TOF MR angiography as measured with the following: lumen depiction scores in all segments (mean, 4.7±0.1 [standard error of the mean]; vs 3.0±0.3 for arterial inflow, 4.1±0.3 vs 1.9±0.3 for arterial outflow, 3.7±0.3 vs 1.8±0.2 for anastomosis, and 4.5±0.2 vs 2.1±0.2 for venous outflow; P<.001), intraluminal signal homogeneity (0.3±0.02 vs 0.4±0.06, P=.005), and CNR efficiency in the venous outflow (5.1±0.6 vs 2.5±0.4, P=.01).
CONCLUSION: This study demonstrates the feasibility of using ferumoxytol-enhanced MR angiography in imaging hemodialysis fistulas with consistently superior image quality compared with nonenhanced TOF MR angiography. © RSNA, 2012

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875796      PMCID: PMC3480811          DOI: 10.1148/radiol.12112694

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2007-02-07       Impact factor: 11.527

3.  How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

4.  Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients.

Authors:  Robert Landry; Paula M Jacobs; Robert Davis; Magdy Shenouda; W Kline Bolton
Journal:  Am J Nephrol       Date:  2005-07-28       Impact factor: 3.754

Review 5.  Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.

Authors:  Hamm Bernd; Eric De Kerviler; Sophie Gaillard; Bruno Bonnemain
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

6.  The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.

Authors:  Bruce S Spinowitz; Michael H Schwenk; Paula M Jacobs; W Kline Bolton; Mark R Kaplan; Chaim Charytan; Marilyn Galler
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

7.  Failing hemodialysis arteriovenous fistula and percutaneous treatment: imaging with CT, MRI and digital subtraction angiography.

Authors:  E Cavagna; P D'Andrea; F Schiavon; G Tarroni
Journal:  Cardiovasc Intervent Radiol       Date:  2000 Jul-Aug       Impact factor: 2.740

8.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

9.  Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Authors:  Robert Provenzano; Brigitte Schiller; Madhumathi Rao; Daniel Coyne; Louis Brenner; Brian J G Pereira
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

Review 10.  Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?

Authors:  Edward A Neuwelt; Bronwyn E Hamilton; Csanad G Varallyay; William R Rooney; Robert D Edelman; Paula M Jacobs; Suzanne G Watnick
Journal:  Kidney Int       Date:  2008-10-08       Impact factor: 10.612

View more
  23 in total

1.  Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease.

Authors:  Joy P Walker; Emily Nosova; Monica Sigovan; Joseph Rapp; Marlene S Grenon; Christopher D Owens; Warren J Gasper; David A Saloner
Journal:  Ann Vasc Surg       Date:  2014-09-28       Impact factor: 1.466

Review 2.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

Review 3.  A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.

Authors:  Yì Xiáng J Wáng; Jean-Marc Idée
Journal:  Quant Imaging Med Surg       Date:  2017-02

4.  Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.

Authors:  Nichanan Ruangwattanapaisarn; Albert Hsiao; Shreyas S Vasanawala
Journal:  Pediatr Radiol       Date:  2014-11-27

5.  Accelerated ferumoxytol-enhanced 4D multiphase, steady-state imaging with contrast enhancement (MUSIC) cardiovascular MRI: validation in pediatric congenital heart disease.

Authors:  Ziwu Zhou; Fei Han; Stanislas Rapacchi; Kim-Lien Nguyen; Daniel Z Brunengraber; Grace-Hyun J Kim; J Paul Finn; Peng Hu
Journal:  NMR Biomed       Date:  2016-11-11       Impact factor: 4.044

6.  Ferumoxytol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment.

Authors:  Christopher J R Gallo; Joseph G Mammarappallil; David Y Johnson; Hamid Chalian; James Ronald; Mustafa R Bashir; Charles Y Kim
Journal:  Radiol Cardiothorac Imaging       Date:  2020-11-19

Review 7.  Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Authors:  Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt
Journal:  Kidney Int       Date:  2017-04-20       Impact factor: 10.612

Review 8.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

9.  High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.

Authors:  Anjali B Nayak; Aarti Luhar; Mark Hanudel; Barbara Gales; Theodore R Hall; J Paul Finn; Isidro B Salusky; Joshua Zaritsky
Journal:  Pediatr Nephrol       Date:  2014-09-12       Impact factor: 3.714

10.  MR Angiography of Renal Transplant Vasculature with Ferumoxytol:: Comparison of High-Resolution Steady-State and First-Pass Acquisitions.

Authors:  Michael T Corwin; Ghaneh Fananapazir; Abhijit J Chaudhari
Journal:  Acad Radiol       Date:  2015-12-18       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.